BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Lymphocytic Leukemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Lymphocytic L
 eukemia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06637501-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06637501)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Sonrotoclax Combined With Zanubrutinib Ver
 sus Zanubrutinib Alone in Participants With Previously Untreated Chronic L
 ymphocytic Leukemia\nEstimated primary completion: November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06637501
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895436-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04895436)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy to Assess Change in Disease Activity and Adverse Events of Oral Veneto
 clax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurri
 ng Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0489
 5436
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895436-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04895436)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study to Assess Change in Disease Activity and Adverse Events of Oral Vene
 toclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recur
 ring Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04895436
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03467867-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03467867)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refracto
 ry CLL\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03467867
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03467867-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03467867)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed
 /Refractory CLL\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03467867
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05147467-2883@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT05147467)
DESCRIPTION:Lisaftoclax\, phase 2\, Relapsed/Refractory Chronic Lymphocytic
  Leukemia.\nStudy: Study of APG-2575 in Patients With Relapsed/Refractory 
 CLL/SLL\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05147467
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03513562-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03513562)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic
  Leukemia and Ibrutinib Resistance Mutations\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03513562
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03513562-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03513562)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax and Ibrutinib in Treating in Participants With Chronic Lymphocyti
 c Leukemia and Ibrutinib Resistance Mutations\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03513562
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06466122-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06466122)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Pi
 rtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With C
 LL or SLL Resistant to Covalent BTKi\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 466122
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757647-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06757647)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lym
 phocytic Lymphoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06757647
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06466122-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06466122)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients Wit
 h CLL or SLL Resistant to Covalent BTKi\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtob
 rutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06466122
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05873712-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05873712)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of 
 Richter's Syndrome\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05873712
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04679012-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04679012)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects Wi
 th Richter's Transformation\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04679012
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03824483-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03824483)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy of Zanubrutinib\, Obinutuzumab\, and Venetoclax in Patients With Chron
 ic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)\nEstimat
 ed primary completion: February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03824483
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03824483-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT03824483)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of Zanubrutinib\, Obinutuzumab\, and Venetoclax in Patients With Chr
 onic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03824483
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722172-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04722172)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinut
 uzumab in People With CLL or SLL\nEstimated primary completion: February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0472217
 2
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722172-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04722172)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinu
 tuzumab in People With CLL or SLL\nEstimated primary completion: February 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04722
 172
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03824483-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT03824483)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Study of Zanubrutinib\, Obinutuzumab\, and Venetoclax in Patien
 ts With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (
 SLL)\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03824483
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02846623-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02846623)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: At
 ezolizumab\, Obinutuzumab\, and Venetoclax in Treating Patients With Chron
 ic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, or Relapsed or Refr
 actory Richter Syndrome\nEstimated primary completion: 28 February 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT02846623
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02846623-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02846623)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Atezolizumab\, Obinutuzumab\, and Venetoclax in Treating Patients With Chr
 onic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, or Relapsed or Re
 fractory Richter Syndrome\nEstimated primary completion: 28 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02846623
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650723-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05650723)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Za
 nubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leuke
 mia (CLL) With Response-based Obinutuzumab\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 650723
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650723-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05650723)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leu
 kemia (CLL) With Response-based Obinutuzumab\nEstimated primary completion
 : March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05650723
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650723-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05650723)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymp
 hocytic Leukemia (CLL) With Response-based Obinutuzumab\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05650723
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03153202-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03153202)
DESCRIPTION:Ibrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Study to 
 Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizuma
 b in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymph
 oma (MCL)\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03153202
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847957-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07847957)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL\nEstimated primary c
 ompletion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07847957
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847957-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT07847957)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL\nEstimated primary
  completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07847957
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674810-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07674810)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Phase 2 Trial Of The Combination Of Zanubrutinib\, Sonrotoclax\, And Obi
 nutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia\
 nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07674810
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674810-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07674810)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Phase 2 Trial Of The Combination Of Zanubrutinib\, Sonrotoclax\
 , And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic 
 Leukemia\nEstimated primary completion: 30 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07674810
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674810-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07674810)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Phase 2 Trial Of The Combination Of Zanubrutinib\, Sonrotocla
 x\, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocyti
 c Leukemia\nEstimated primary completion: 30 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07674810
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)\, 
 With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previo
 usly Untreated CLL\nEstimated primary completion: 30 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)\
 , With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Prev
 iously Untreated CLL\nEstimated primary completion: 30 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)
 \, With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Pre
 viously Untreated CLL\nEstimated primary completion: 30 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04419519-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04419519)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: As
 sessing Minimal Residual Disease by Next- Generation Sequencing to Minimiz
 e Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
 \nEstimated primary completion: May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04419519
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624554-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05624554)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Prev
 iously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
 CLL/SLL) Without TP53 Aberrations (MK-1026-008\, BELLWAVE-008)\nEstimated 
 primary completion: 19 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05624554
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04458610-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04458610)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Zanubrutinib and Rituximab for the Treatment of Previously Untreate
 d Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated pr
 imary completion: 26 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04458610
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04458610-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT04458610)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Rituximab for the Treatment of Previously Untr
 eated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimate
 d primary completion: 26 May 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04458610
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03128879-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03128879)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL\nEstima
 ted primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03128879
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03128879-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03128879)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL\nEstim
 ated primary completion: 31 May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03128879
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03128879-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03128879)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL\nEs
 timated primary completion: 31 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03128879
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003464-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07003464)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase II Trial of Zanubrutinib\, Obinutuzumab\, Bendamustine (ZGB) as Firs
 t-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study\nEs
 timated primary completion: 1 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07003464
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003464-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07003464)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Phase II Trial of Zanubrutinib\, Obinutuzumab\, Bendamustine (Z
 GB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Cente
 r Study\nEstimated primary completion: 1 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07003464
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03960840-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03960840)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Phase I/II Study of Rapcabtagene Autoleucel in CLL\, 3L+ DLBCL\, r/r ALL a
 nd 1L HR LBCL\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03960840
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04505254-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04505254)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Le
 ukemia\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04505254
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04505254-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04505254)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic L
 eukemia\nEstimated primary completion: 30 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04505254
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04447768-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04447768)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Th
 e Combination of Venetoclax and Obinutuzumab in People With Chronic Lympho
 cytic Leukemia (CLL)\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04447768
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04447768-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04447768)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymp
 hocytic Leukemia (CLL)\nEstimated primary completion: July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04447768
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02756897-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02756897)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocyt
 ic Leukemia\nEstimated primary completion: 1 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02756897
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02756897-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02756897)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocy
 tic Leukemia\nEstimated primary completion: 1 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02756897
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333262-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06333262)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leuke
 mia\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06333262
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333262-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06333262)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leuk
 emia\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06333262
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab
  in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic
  Lymphoma\nEstimated primary completion: 15 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzum
 ab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocyt
 ic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzu
 mab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocy
 tic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05718869-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05718869)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Tafasitamab and Zanubrutinib for the Treatment of Patients With
  Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
 a\, TaZA CLL Study\nEstimated primary completion: 27 July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05718869
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04941716-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04941716)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ac
 alabrutinib in Combination With Venetoclax for the Treatment of Refractory
  or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\,
  The AVENUE-2 Trial\nEstimated primary completion: 10 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04941716
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04941716-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04941716)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib in Combination With Venetoclax for the Treatment of Refract
 ory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
 a\, The AVENUE-2 Trial\nEstimated primary completion: 10 August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04941716
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05672173-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05672173)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Lis
 ocabtagene Maraleucel\, Nivolumab and Ibrutinib for the Treatment of Richt
 er's Transformation\nEstimated primary completion: 24 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05672173
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03162536-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270917
DTEND;VALUE=DATE:20270918
SUMMARY:Nemtabrutinib: Phase 1/2 readout est. (NCT03162536)
DESCRIPTION:Nemtabrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Ref
 ractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)\nEstimated prim
 ary completion: 17 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03162536
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05254743-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT05254743)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With
  Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05254743
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271667-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07271667)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inh
 ibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and 
 Other B-cell Malignancies\nEstimated primary completion: November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07271667
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03331198-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03331198)
DESCRIPTION:Ibrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: S
 tudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed o
 r Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymph
 oma (SLL)\nEstimated primary completion: 26 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03331198
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03331198-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03331198)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed 
 or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymp
 homa (SLL)\nEstimated primary completion: 26 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03331198
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refract
 ory Chronic Lymphocytic Leukemia and Richter's Syndrome\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04623541
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pirtobrutinib: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Pirtobrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refr
 actory Chronic Lymphocytic Leukemia and Richter's Syndrome\nEstimated prim
 ary completion: December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Safety and Efficacy Study of Epcoritamab in Subjects With Relapse
 d/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome\nEstimate
 d primary completion: December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT06958705)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ven
 etoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monoth
 erapy\nEstimated primary completion: 1 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06958705)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monot
 herapy\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06958705)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Mo
 notherapy\nEstimated primary completion: 1 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06958705)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Venetoclax as Consolidation in CLL Patients Treated With BTK In
 hibitor Monotherapy\nEstimated primary completion: 1 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05963074-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05963074)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A S
 tudy to Customize Ibrutinib Treatment Regimens for Participants With Previ
 ously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completion
 : 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05963074
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05963074-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05963074)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Customize Ibrutinib Treatment Regimens for Participants With Prev
 iously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completio
 n: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05963074
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557056-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07557056)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ne
 mtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymp
 hocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07557056
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734038-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07734038)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukem
 ia and Small Lymphocytic Lymphoma\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07734
 038
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671378-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07671378)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-
 Naïve\, High-Risk CLL/SLL Patients\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 671378
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685717-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07685717)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocy
 tic Leukemia\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07685717
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671378-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07671378)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatmen
 t-Naïve\, High-Risk CLL/SLL Patients\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07671378
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734038-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07734038)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymph
 ocytic Leukemia and Small Lymphocytic Lymphoma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07734038
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557056-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07557056)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic L
 ymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nemtabrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07557056
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221500-10973@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:bexobrutideg: Phase 2 readout est. (NCT07221500)
DESCRIPTION:bexobrutideg\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton
 's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak C
 LL-201)\nEstimated primary completion: January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07221500
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043674-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06043674)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin\, Pirto
 brutinib\, or Atezolizumab in Richter's Transformation\nEstimated primary 
 completion: 15 January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06043674
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043674-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06043674)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin\, Pirt
 obrutinib\, or Atezolizumab in Richter's Transformation\nEstimated primary
  completion: 15 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06043674
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Particip
 ants Receiving Oral Venetoclax in Combination With Intravenously Infused O
 binutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphoc
 ytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Partic
 ipants Receiving Oral Venetoclax in Combination With Intravenously Infused
  Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymph
 ocytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Parti
 cipants Receiving Oral Venetoclax in Combination With Intravenously Infuse
 d Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymp
 hocytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560322-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04560322)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL\nEstimated primary comp
 letion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04560322
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560322-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04560322)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL\nEstimated primary co
 mpletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04560322
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560322-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04560322)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL\nEstimated primary c
 ompletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/acalabrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04560322
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849713-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06849713)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Zanubrutinib\, Obinutuzumab\, Sonrotoclax (BOSon) or BGB-16673\, Obinutuzu
 mab\, Sonrotoclax (DOSon) in TN CLL/SLL\nEstimated primary completion: 1 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6849713
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849713-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06849713)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: Zanubrutinib\, Obinutuzumab\, Sonrotoclax (BOSon) or BGB-16673\, 
 Obinutuzumab\, Sonrotoclax (DOSon) in TN CLL/SLL\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06849713
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849713-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06849713)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib\, Obinutuzumab\, Sonrotoclax (BOSon) or BGB-16673\
 , Obinutuzumab\, Sonrotoclax (DOSon) in TN CLL/SLL\nEstimated primary comp
 letion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06849713
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02629809-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02629809)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ibr
 utinib\, Fludarabine Phosphate\, Cyclophosphamide\, and Obinutuzumab in Tr
 eating Patients With Chronic Lymphocytic Leukemia\nEstimated primary compl
 etion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02629809
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02629809-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02629809)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Ibrutinib\, Fludarabine Phosphate\, Cyclophosphamide\, and Obinutuzumab in
  Treating Patients With Chronic Lymphocytic Leukemia\nEstimated primary co
 mpletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02629809
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536349-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05536349)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ti
 me-limited Triplet Combination of Pirtobrutinib\, Venetoclax\, and Obinutu
 zumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL
 ) or Richter Transformation (RT)\nEstimated primary completion: 25 April 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05536349
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536349-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05536349)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Time-limited Triplet Combination of Pirtobrutinib\, Venetoclax\, and Obinu
 tuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (C
 LL) or Richter Transformation (RT)\nEstimated primary completion: 25 April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05536
 349
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536349-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05536349)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Time-limited Triplet Combination of Pirtobrutinib\, Venetoclax\, and Obin
 utuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (
 CLL) or Richter Transformation (RT)\nEstimated primary completion: 25 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 36349
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197192-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05197192)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Phase-3-trial of Acalabrutinib\, Obinutuzumab & Venetoclax Compared to Obi
 nutuzumab and Venetoclax in Previously Untreated Patients With High Risk C
 LL\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05197192
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197192-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05197192)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Phase-3-trial of Acalabrutinib\, Obinutuzumab & Venetoclax Compared to O
 binutuzumab and Venetoclax in Previously Untreated Patients With High Risk
  CLL\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05197192
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197192-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05197192)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Phase-3-trial of Acalabrutinib\, Obinutuzumab & Venetoclax Compared to 
 Obinutuzumab and Venetoclax in Previously Untreated Patients With High Ris
 k CLL\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05197192
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Ibrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: Ass
 essing the Ability of Combination Treatment With Venetoclax to Permit Time
  Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary comple
 tion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03701282
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: As
 sessing the Ability of Combination Treatment With Venetoclax to Permit Tim
 e Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary compl
 etion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03701282
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Assessing the Ability of Combination Treatment With Venetoclax to Permit T
 ime Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary com
 pletion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03701282
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588478-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06588478)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participan
 ts With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocy
 tic Lymphoma\nEstimated primary completion: June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06588478
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014917-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07014917)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: In
 termittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL\nEs
 timated primary completion: 5 June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07014917
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014917-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07014917)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL\
 nEstimated primary completion: 5 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07014917
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02007044-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02007044)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ibr
 utinib With or Without Rituximab in Treating Patients With Relapsed Chroni
 c Lymphocytic Leukemia\nEstimated primary completion: 30 June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT02007044
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01446133-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT01446133)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Le
 ukemia/Small Lymphocytic Lymphoma (CLL-SLL)\nEstimated primary completion:
  30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 01446133
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02007044-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT02007044)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Ibrutinib With or Without Rituximab in Treating Patients With Relap
 sed Chronic Lymphocytic Leukemia\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02007044
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169737-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04169737)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ac
 alabrutinib and Venetoclax With or Without Early Obinutuzumab for the Trea
 tment of High Risk\, Recurrent\, or Refractory Chronic Lymphocytic Leukemi
 a or Small Lymphocytic Lymphoma\nEstimated primary completion: 9 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04169737
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169737-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04169737)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Tr
 eatment of High Risk\, Recurrent\, or Refractory Chronic Lymphocytic Leuke
 mia or Small Lymphocytic Lymphoma\nEstimated primary completion: 9 July 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04169737
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169737-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04169737)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the T
 reatment of High Risk\, Recurrent\, or Refractory Chronic Lymphocytic Leuk
 emia or Small Lymphocytic Lymphoma\nEstimated primary completion: 9 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041697
 37
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants With 
 Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mantle Cel
 l Lymphoma\nEstimated primary completion: 1 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants
  With Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mant
 le Cell Lymphoma\nEstimated primary completion: 1 August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants Wit
 h Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mantle C
 ell Lymphoma\nEstimated primary completion: 1 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812246-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07812246)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chroni
 c Lymphocytic Leukemia /Small Lymphocytic Leukemia\, ZeuS-2 Trial\nEstimat
 ed primary completion: 13 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07812246
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812246-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07812246)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chro
 nic Lymphocytic Leukemia /Small Lymphocytic Leukemia\, ZeuS-2 Trial\nEstim
 ated primary completion: 13 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07812246
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979076-466@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:MS-553: Phase 1/2 readout est. (NCT06979076)
DESCRIPTION:MS-553\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: A Ph
 ase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Ref
 ractory or Relapsed CLL/SLL\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ms-553#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06979076
URL:https://assetmemo.bio/drug/ms-553#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624799-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07624799)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immu
 no-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chro
 nic Lymphocytic Leukemia (CLL).\nEstimated primary completion: 1 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07624
 799
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624799-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07624799)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Imm
 uno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chr
 onic Lymphocytic Leukemia (CLL).\nEstimated primary completion: 1 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 24799
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321652-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT07321652)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: Testing the Addition of Anti-Cancer Drug Sonrotoclax\, to the Sta
 ndard Treatment Zanubrutinib\, for Previously Untreated CLL/SLL\nEstimated
  primary completion: 30 September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07321652
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644183-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06644183)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapse
 d Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: 1 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0664
 4183
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644183-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06644183)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractor
 y/Relapsed Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completio
 n: 1 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06644183
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04269902-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04269902)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: Te
 sting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leuk
 emia (CLL) or Small Lymphocytic Leukemia (SLL)\, EVOLVE CLL/SLL Study\nEst
 imated primary completion: 1 October 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04269902
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04269902-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04269902)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Le
 ukemia (CLL) or Small Lymphocytic Leukemia (SLL)\, EVOLVE CLL/SLL Study\nE
 stimated primary completion: 1 October 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04269902
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03516617-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281111
DTEND;VALUE=DATE:20281112
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT03516617)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early
 -Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimat
 ed primary completion: 11 November 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03516617
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03516617-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281111
DTEND;VALUE=DATE:20281112
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03516617)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib With or Without Obinutuzumab in Treating Patients With Earl
 y-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstima
 ted primary completion: 11 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03516617
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Ibrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: M
 osunetuzumab for CLL MRD Clearance\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07052
 695
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: Mosunetuzumab for CLL MRD Clearance\nEstimated primary completion: 31 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07052695
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pirtobrutinib: Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Pirtobrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: Mosunetuzumab for CLL MRD Clearance\nEstimated primary completion: 31 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07052695
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Chronic Lymphocytic Leuke
 mia.\nStudy: Mosunetuzumab for CLL MRD Clearance\nEstimated primary comple
 tion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07052695
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899398-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07899398)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted 
 Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-
 limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Tre
 atment-naïve CLL\nEstimated primary completion: 1 January 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07899398
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899398-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07899398)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Trial to Evaluate the Efficacy and Safety of a Fitness-adapte
 d Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Tim
 e-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With T
 reatment-naïve CLL\nEstimated primary completion: 1 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07899398
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739459-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07739459)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Study of Zanubrutinib in Older Patients With Previously Untreat
 ed Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: April
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07739
 459
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582159-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07582159)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ta
 fasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic L
 ymphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completi
 on: 14 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07582159
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582159-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07582159)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chroni
 c Lymphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary compl
 etion: 14 April 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /acalabrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07582159
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812715-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06812715)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutin
 ib After Previous Treatment With Zanubrutinib\nEstimated primary completio
 n: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06812715
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024706-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07024706)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: MA
 VRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relaps
 ed After a Course of BTKi + BCL2i Combination\, With or Without Obinutuzum
 ab\nEstimated primary completion: 1 May 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07024706
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024706-3339@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07024706)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Rel
 apsed After a Course of BTKi + BCL2i Combination\, With or Without Obinutu
 zumab\nEstimated primary completion: 1 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07024706
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458297-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT05458297)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combinati
 on in Participants With Aggressive and Indolent B-cell Malignancies (MK-21
 40-006)\nEstimated primary completion: 17 May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05458297
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978088-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06978088)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic
  Lymphoma (CLL/SLL) and Variants of This\nEstimated primary completion: 1 
 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6978088
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863402-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT06863402)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformati
 on\, Diffuse Large B-cell Lymphoma Subtype\nEstimated primary completion: 
 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nemtabru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06863402
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218510-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290608
DTEND;VALUE=DATE:20290609
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07218510)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Unt
 reated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma\, LonGE
 Vity Trial\nEstimated primary completion: 8 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07218510
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218510-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290608
DTEND;VALUE=DATE:20290609
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07218510)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of U
 ntreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma\, Lon
 GEVity Trial\nEstimated primary completion: 8 June 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07218510
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364423-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06364423)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leuk
 emias\nEstimated primary completion: 1 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06364423
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06943872)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obi
 nutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Ritu
 ximab Treatment In Patients With Relapsed and/or Refractory Chronic Lympho
 cytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEstimated pri
 mary completion: 30 September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06943872)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Progression-Free Survival With Sonrotoclax
  Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax 
 Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chron
 ic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEsti
 mated primary completion: 30 September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06943872)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Chronic Lymphocytic Leukemia.\n
 Study: A Study to Investigate Progression-Free Survival With Sonrotoclax P
 lus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Pl
 us Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic
  Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEstima
 ted primary completion: 30 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516093-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT07516093)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL\nEstimated primary c
 ompletion: October 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07516093
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516093-10973@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:bexobrutideg: Phase 3 readout est. (NCT07516093)
DESCRIPTION:bexobrutideg\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL\nEstimated primary co
 mpletion: October 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bexobrutideg#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07516093
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194980-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291020
DTEND;VALUE=DATE:20291021
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07194980)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/
 Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\nEstima
 ted primary completion: 20 October 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07194980
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Mantle Cell Lymphoma.\nStud
 y: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) Whe
 n Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEstim
 ated primary completion: 30 November 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Mantle Cell Lymphoma.\nSt
 udy: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) W
 hen Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEst
 imated primary completion: 30 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154264-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07154264)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)\nEstimated primary co
 mpletion: December 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07154264
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690891-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07690891)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ne
 mtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymp
 hocytic Leukemia\nEstimated primary completion: 1 December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07690891
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690891-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07690891)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Ly
 mphocytic Leukemia\nEstimated primary completion: 1 December 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07690891
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690891-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07690891)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic L
 ymphocytic Leukemia\nEstimated primary completion: 1 December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nemtabrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07690891
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738887-2041@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT07738887)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Epc
 oritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocyt
 ic Leukemia With TP53 Alterations\nEstimated primary completion: 31 Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077388
 87
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738887-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07738887)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ep
 coritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocy
 tic Leukemia With TP53 Alterations\nEstimated primary completion: 31 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0773
 8887
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06367374-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06367374)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SL
 L\nEstimated primary completion: 28 February 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06367374
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06367374-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06367374)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/
 SLL\nEstimated primary completion: 28 February 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06367374
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520098-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06520098)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or With
 out Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small L
 ymphocytic Lymphoma (SLL)\nEstimated primary completion: 30 June 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06520098
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860775-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07860775)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma W
 ith Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Bac
 k After Previous Treatment.\nEstimated primary completion: 15 October 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07860775
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378138-2932@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301125
DTEND;VALUE=DATE:20301126
SUMMARY:Mesutoclax: Phase 2/3 readout est. (NCT06378138)
DESCRIPTION:Mesutoclax\, phase 2/3\, Chronic Lymphocytic Leukemia.\nStudy: 
 ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymp
 hocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)\nEstimated primary c
 ompletion: 25 November 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mesutoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06378138
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02966756-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02966756)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Venetoclax in Participants With Relapsed or Refractory Chronic Ly
 mphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ven
 etoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02966756
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796373-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07796373)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Le
 ukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pi
 rtobrutinib and Previously Treated With a BCL2 Inhibitor\nEstimated primar
 y completion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07796373
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277231-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT07277231)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib 
 (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Prev
 iously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completio
 n: February 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/son
 rotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07277231
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277231-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT07277231)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Chronic Lymphocytic Leukemi
 a.\nStudy: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutini
 b (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Pr
 eviously Untreated Chronic Lymphocytic Leukemia\nEstimated primary complet
 ion: February 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 anubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07277231
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967610-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06967610)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ph
 ase II Study of Combined Pirtobrutinib\, Venetoclax and Obinutuzumab (PVO)
  Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Le
 ukemia/Small Lymphocytic Lymphoma (CLL/SLL).\nEstimated primary completion
 : 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06967610
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967610-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06967610)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Phase II Study of Combined Pirtobrutinib\, Venetoclax and Obinutuzumab (PV
 O) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic 
 Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).\nEstimated primary completi
 on: 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06967610
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967610-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06967610)
DESCRIPTION:Pirtobrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Phase II Study of Combined Pirtobrutinib\, Venetoclax and Obinutuzumab (P
 VO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic
  Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).\nEstimated primary complet
 ion: 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pir
 tobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06967610
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887061-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07887061)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Tacabrutideg and Sonrotoclax\, With Response-Guided Obinutuzumab\, for the
  Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphom
 a (SLL)\nEstimated primary completion: 1 July 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07887061
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887061-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07887061)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: Tacabrutideg and Sonrotoclax\, With Response-Guided Obinutuzumab\
 , for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocyti
 c Lymphoma (SLL)\nEstimated primary completion: 1 July 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07887061
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508995-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07508995)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 
 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatmen
 t-Naive Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: 
 1 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sonrotoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07508995
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06073821-2909@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06073821)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Com
 pared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymph
 ocytic Leukemia (CLL)\nEstimated primary completion: February 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06073821
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06073821-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT06073821)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Chronic Lymphocytic Leukemi
 a.\nStudy: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) C
 ompared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lym
 phocytic Leukemia (CLL)\nEstimated primary completion: February 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06073821
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544785-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06544785)
DESCRIPTION:Obinutuzumab\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocy
 tic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary completion: 
 31 May 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06544785
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544785-10908@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06544785)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Chronic Lymphocytic Leukemi
 a.\nStudy: Zanubrutinib With Obinutuzumab in Untreated Patients With Chron
 ic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary c
 ompletion: 31 May 2032. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06544785
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947851-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320601
DTEND;VALUE=DATE:20320602
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05947851)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in S
 econd-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/S
 mall Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).\nEstimated
  primary completion: 1 June 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05947851
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947851-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320601
DTEND;VALUE=DATE:20320602
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05947851)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) i
 n Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemi
 a/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).\nEstima
 ted primary completion: 1 June 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05947851
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136559-11239@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320907
DTEND;VALUE=DATE:20320908
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT06136559)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choi
 ce of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic L
 eukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
 \nEstimated primary completion: 7 September 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06136559
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-2078@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of NX-5948 in Combination With Other Agents in Adults With B-cell Ma
 lignancies\nEstimated primary completion: May 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-2649@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Study of NX-5948 in Combination With Other Agents in Adults With B-cell 
 Malignancies\nEstimated primary completion: May 2033. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Study of NX-5948 in Combination With Other Agents in Adults With 
 B-cell Malignancies\nEstimated primary completion: May 2033. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-10973@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:bexobrutideg: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:bexobrutideg\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Study of NX-5948 in Combination With Other Agents in Adults With B-cell 
 Malignancies\nEstimated primary completion: May 2033. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220187-3359@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20351001
DTEND;VALUE=DATE:20351002
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT07220187)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnos
 ed Richter Transformation\, The PIRAMID Trial\nEstimated primary completio
 n: 1 October 2035. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pi
 rtobrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07220187
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220187-4915@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20351001
DTEND;VALUE=DATE:20351002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07220187)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Adding Pirtobrutinib to the Usual Treatment for People With Newly 
 Diagnosed Richter Transformation\, The PIRAMID Trial\nEstimated primary co
 mpletion: 1 October 2035. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07220187
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
